Literature DB >> 8505459

The methodology of studying decline in Alzheimer's disease.

J O Brooks1, H C Kraemer, E D Tanke, J A Yesavage.   

Abstract

OBJECTIVE: To present a new model for analyzing longitudinal data. The trilinear model is superior to the commonly used linear model that includes the flawed assumption that decline is uniform throughout the course of disease--an assumption that does not correspond to clinical observations.
DESIGN: A longitudinal cohort sample was used to compare the linear and trilinear models. Simulated longitudinal data were generated to assess classification errors with the trilinear model. SUBJECTS AND
SETTING: The subjects were 80 patients with Alzheimer's disease tested in a hospital out-patient clinic.
METHODS: The trilinear model describes Alzheimer's disease as proceeding through three periods: An initial period of stability before detectable decline, a period of decline, and a final period of stability during which there is no further detectable decline. A program for the Apple Macintosh computer is available at no charge to apply the model to data.
FINDINGS: The analyses indicated that the trilinear model provides a better reflection of decline in Alzheimer's disease than does the linear model. This advantage is present whether the periods of stability reflect a "true" lack of decline or insensitivity of a measurement instrument.
CONCLUSIONS: The trilinear model provides not only a more accurate estimate of the average rate of change, but also (when possible) estimates of the point at which decline begins and ends. Also, more detailed comparisons of tests could be made by using the trilinear parameters. The trilinear model would benefit researchers engaged in longitudinal research of progressive disorders.

Entities:  

Mesh:

Year:  1993        PMID: 8505459     DOI: 10.1111/j.1532-5415.1993.tb06734.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  10 in total

1.  Predictors of mortality in patients with Alzheimer's disease living in nursing homes.

Authors:  G Gambassi; F Landi; K L Lapane; A Sgadari; V Mor; R Bernabei
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

2.  Gene Expressions, Hippocampal Volume Loss, and MMSE Scores in Computation of Progression and Pharmacologic Therapy Effects for Alzheimer's Disease.

Authors:  Aydin Saribudak; Adarsha A Subick; Na Hyun Kim; Joshua A Rutta; M Umit Uyar
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2018-09-14       Impact factor: 3.710

Review 3.  Modeling the time-course of Alzheimer dementia.

Authors:  J W Ashford; F A Schmitt
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

4.  Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.

Authors:  F Nourhashémi; M G Olde Rikkert; A Burns; B Winblad; G B Frisoni; J Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

5.  The transitional association between β-amyloid pathology and regional brain atrophy.

Authors:  Philip S Insel; Niklas Mattsson; Michael C Donohue; R Scott Mackin; Paul S Aisen; Clifford R Jack; Leslie M Shaw; John Q Trojanowski; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

6.  Factors affecting the age of onset and rate of progression of Alzheimer's disease.

Authors:  J V Bowler; D G Munoz; H Merskey; V Hachinski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

7.  A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort.

Authors:  Bruno M Jedynak; Andrew Lang; Bo Liu; Elyse Katz; Yanwei Zhang; Bradley T Wyman; David Raunig; C Pierre Jedynak; Brian Caffo; Jerry L Prince
Journal:  Neuroimage       Date:  2012-08-03       Impact factor: 6.556

8.  Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients?

Authors:  E Capitani; A Francescani; H Spinnler
Journal:  Neurol Sci       Date:  2007-10-31       Impact factor: 3.307

9.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

10.  An overview of longitudinal data analysis methods for neurological research.

Authors:  Joseph J Locascio; Alireza Atri
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.